A recent publication demonstrates the close connection between immune dysfunction in T cells and neutrophils that can be targeted by interfering with microbial sequestration in the spleen or by eliminating circulating chromatin. The presence of G-CSF and circulating histones in many conditions suggests that they may be critical drivers of immune dysfunction that could be …
A new publication highlights a potential role of neutrophils in pulmonary long COVID. Individuals who had persistent pulmonary symptoms, showed a neutrophil-associated inflammatory phenotype and evidence of NETs in blood. The publication was published on Nov. 16 in Science Translational Medicine. It is also co-authored by Dr Andrew Aswani – our Chief Medical Officer. Interstitial lung disease …
A new publication suggests that deficient DNA clearance is linked to increased mortality in individuals with severe COVID-19 pneumonia. The publication was accepted on Nov. 15 and will soon appear in Immunity. It is co-authored by Prof Sascha David, Dr Klaus Stahl and Dr Christian Bode, who will take part in the future of Santersus as Principle Investigators …
Physiology and biological impact of removing circulating cell-free DNA/Neutrophil Extracellular Trap (cfDNA/NET) on modifying lung injury at University of Edinburgh on FindAPhD.com In critically ill patients, cell free DNA (cfDNA), a danger signal capable of initiating intense innate immune responses, is measurable in circulation. Higher levels of cfDNA in circulation is associated with greater inflammatory …
Santersus AG, a privately held therapeutic apheresis company, announced today that their medical device product, NucleoCapture, has been granted designation as a Breakthrough Device by The Center for Devices and Radiological Health (CDRH) of the US Food and Drug Administration (FDA). The indication cited in the breakthrough designation is as an adjunctive treatment to antibiotics …
It was shown that circulating NETs might support Inflamm-ageing chronic low grade inflammation typical of ageing, being common biological factor responsible for the decline and the onset of disease in the elderly. At Santersus, we are investigating the use of NucleoCapture to prevent inflamm-ageing and slow down functional decline in the elderly.
Santersus AG announces the successful completion of their first in human clinical trials relating to Sepsis and COVID-19. First trial started in Feb 2021 in Sepsis/COVID-19 Recruitment completed in September 2021 with 10 patients Interim analysis showed safe, easy to apply, confirmed the reduction in NETs with a strong temporal association with clinical improvement
Santersus has released an abstract at the International Society for Apheresis meeting (ISFA), which is being held virtually this year. The poster presentation entitled “Therapeutic Removal of NETs from Blood in a Pig Model of Sepsis” was given by Dr. Andrew Aswani, the Chief Medical Officer of Santersus AG. Data clearly showed that the application …
Santersus’ therapeutic technology helps to treat sepsis Read More »